Gentamicin Ointment
gentamicin 0.3% · ophthalmic ointment
Antibiotic
Approved uses
Ocular bacterial infection: conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcer, blepharitis, blepharoconjunctivitis, acute meibomianitis, dacryocystitis
Approximately 1/2 inch ribbon to the affected eye(s) 2 or 3 times daily
Stays detectable on the ocular surface about 40 minutes versus 10 minutes for the drop.
Contraindications
Known hypersensitivity to any of the components.
0.3% (3 mg/g) ointment, 3.5 g tube, box of one
Aminoglycoside antibiotic, active in vitro against many strains of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. The label gives no mechanism beyond this spectrum. The ointment base is white petrolatum and mineral oil. Aminoglycosides inhibit bacterial protein synthesis by binding to the 30S subunit, which blocks the initiation complex.
Warnings & Precautions
- Not for injection into the eye: Never inject subconjunctivally or introduce directly into the anterior chamber of the eye. A survey of retina specialists reported 93 cases of macular infarction they believed to be related to administration of gentamicin sulfate, and twenty-three cases of macular infarction occurred in eyes treated with prophylactic subconjunctival injections of aminoglycosides after routine ocular surgery.
- Retarded corneal healing: Ophthalmic ointments may retard corneal healing. In an in vitro rabbit corneal epithelial cell culture model, neomycin, gentamicin, tobramycin, and amikacin each inhibited 3H-thymidine incorporation at all tested concentrations after 30 and 60 minutes of exposure.
- Overgrowth of nonsusceptible organisms: Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi, and bacterial resistance to gentamicin may also develop.
- Aggravated discharge, inflammation or pain: If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.
- Irritation or hypersensitivity: If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use and appropriate therapy should be instituted.
Common Side Effects
The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia. Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations, and allergic reactions, thrombocytopenic purpura and hallucinations have occurred rarely.
Pregnancy: Pregnancy Category C, with no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk. Systemic dosing of pregnant rats at approximately 500 times the maximum recommended ophthalmic human dose depressed newborn body weights, kidney weights, and median glomerular counts.
Lactation: This label has no nursing mothers section.
Safety and effectiveness in neonates have not been established.